BCL2 and diffuse large B-cell lymphoma: Recent research indicated that INCB057643 combining with the BCL-2 inhibitor venetoclax displayed potent therapeutic synergy in DLBCL/HGBCL cells with and without concurrent TP53 mutation, which may bring new treatment options to patients with TP53 mutation (Deng et al., 2021).